Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
ID06006806

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy

Led by Covenant Health Cancer Center · Updated on 2025-04-08

100

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating a new technique called "Spot Delete" during pencil beam scanning proton therapy to see if it can reduce skin reactions known as radiation dermatitis in breast cancer patients. This study focuses on patients with stage 0 to III breast cancer and uses a computer model to analyze how the energy of the proton beam relates to these skin reactions. The purpose is to compare the skin effects of this new method to historical data from patients who received regular proton therapy without the technique. The study treatment involves planning proton therapy guided by a CT scan to find the best proton placement. The "Spot Delete" software is used during treatment planning to prevent protons from stopping in the skin, which is thought to cause skin redness. Patients receive pencil beam scanning proton therapy with this technique, and their skin reactions are monitored throughout the treatment period and follow-up. Participants will have digital photos taken of their treated skin area to assess redness without revealing their identity. They will complete self-report questionnaires, and medical staff will document skin reactions using standardized scoring systems. Assessments occur at baseline, weekly after every fifth treatment session, at the end of treatment, and at 1 and 6 months post-treatment. Researchers will compare these results to historical rates of skin reactions and measure the linear energy transfer of the proton beam. The study includes regular evaluations over about 10 weeks of treatment and follow-up.

CONDITIONS

Brief Title

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient consents and signs an approved consent form
  • Age 18 years or older
  • Diagnosis of stage 0, I, II, or III breast cancer
  • Tumor is ductal carcinoma in-situ (DCIS) or invasive adenocarcinoma
  • Has had lumpectomy or mastectomy surgery
  • Estrogen receptor (ER) analysis performed on the primary tumor
  • Progesterone (PgR) analysis desired but not mandatory
  • No serious health conditions affecting ability to complete treatment or skin in treatment area
Not Eligible

You will not qualify if you...

  • Stage IV breast cancer
  • Non-epithelial breast cancers such as sarcoma or lymphoma
  • Paget's disease of the nipple
  • Prior radiation therapy to breast or chest area
  • Collagen vascular diseases like dermatomyositis with high CPK or active rash, systemic lupus erythematosus, or scleroderma
  • Pregnancy or breastfeeding
  • Psychiatric, addictive, or other disorders preventing study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Approximately 10 weeks

Participants receive Pencil Beam Scanning Proton Therapy using the Spot Delete technique to reduce skin radiation dermatitis. Skin reactions are assessed during therapy.

Weekly visits for skin assessments after every fifth treatment session

Follow-up

Duration - 6 months

Participants are monitored for skin reactions post treatment to assess recovery and long-term effects.

2 visits (1-month and 6-month post treatment)

Trial Site Locations

Total: 1 location

1

Thompson Proton Center

Knoxville, Tennessee, United States, 37909

Actively Recruiting

Loading map...

Research Team

S

Samantha Hedrick

C

Chester Ramsey, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

0

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here